Soluble B7-H3 as a Biomarker for Osteosarcoma

An Exploratory Research of Soluble B7-H3 Expression in Peripheral Blood as a Biomarker to Monitor Therapeutic Effect of Systemic Treatment for Osteosarcoma

Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.

Inclusion Criteria:

• High Grade osteosarcoma verified with pathologic diagnosis.
• systemic treatment-naive before the first time Blood drawing.
• ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy.
• All radiographs are complete for clinical evaluation.

Exclusion Criteria:

• Patients who Can't tolerate blood drawing.
• Patients without complete medical records in PKUPH system.
• Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy.
• other conditions that investigators think are not suitable for this study.